At ReproNovo, we are redefining what's possible in reproductive medicine and women’s health.
We are advancing innovative therapeutic solutions for both male and female infertility, as well as pioneering treatment options for uterine conditions like adenomyosis, delivering meaningful change to patients worldwide.
Our international team brings together deep expertise across reproductive medicine, drug development, regulatory strategy, and business development—with a proven track record of bringing multiple therapies to market.
ReproNovo is backed by leading investors including Jeito Capital, AXA IM Alts, M Ventures, Ysios Capital, and ALSA Ventures. Headquartered in Lausanne, Switzerland, our primary development team is located in Copenhagen, Denmark, with an additional development site in Barcelona, Spain.
Imprint
ReproNovo S.A.
Rue de Langallerie 11
1003 Lausanne, Switzerland
E-Mail: info@repronovo.com
Chief Executive Officer & Co-Founder: Jean Duvall
Chief Scientific & Medical Officer & Co-Founder: Joan-Carles Arce
Chief Financial Officer & Co-Founder: BingMei Hao
Company Details
- Employees
- 19
- Founded
- -
- Address
- Rue De Langallerie 11, Lausanne,1003,switzerland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.repronovo.com
- HQ
- Lausanne
Repronovo Questions
Repronovo's website is http://www.repronovo.com
Repronovo's LinkedIn profile is https://ch.linkedin.com/company/repronovo
Repronovo has
19 employees.
View email and phone details for 19
employees at Repronovo.
Repronovo's industry is
Biotechnology Research
Repronovo's top competitors are
Newlimit,
Grin Therapeutics, Inc.,
Syndeio Biosciences,
Stylus Medicine,
Xelidoni,
Cellcentric,
Juvenescence®,
Azafaros B.v.,
Haya Therapeutics,
Ausperbio.
Repronovo's categories are Biotechnology Research
Repronovo's founding year is 2021
